Company Profiles

Print
 
 
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, the Company's R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.
Our Company's success is powered by our more than 16,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.


 

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015.


 
 
Alimera Sciences, founded in June 2003, and proudly established in Europe since 2013, is a pharmaceutical company that specialises in the research, development and commercialisation of prescription ophthalmic pharmaceuticals. We are presently focused on diseases of the retina, affecting millions of people in our aging populations. Our commitment to retina specialists and their patients is manifest in our product and development portfolio designed to treat early- and late-stage diseases such as DMO, AMD, non-infectious uveitis and RVO. Alimera’s focus is to:
• Continue development of our current product portfolio in pursuit of other potential ophthalmic indications.
• Pursue the development, license or acquisition of rights to potential ophthalmic drug delivery technologies and compounds.
• Operate as an ethically driven company, recognising our responsibility to others and the importance of having a positive impact on those with whom we interact.

 
 
CeGaT GmbH
Paul-Ehrlich-Str. 23
72076 Tuebingen, Germany
Email: info@cegat.de
Website: www.cegat.de
CeGaT is a leading global provider of genetic diagnostics and mutation-related disease analyses. The company combines its next-generation sequencing (NGS) process and analysis pipelines with its medical expertise - dedicated to identifying the genetic cause of disease and supporting patient management.Genetic mutations can trigger a wide range of diseases, from epilepsy to eye disorders. Through the use of NGS, it is possible to analyze all genes associated with a disease phenotype simultaneously – both fast and effectively. An interdisciplinary team of scientists and physicians evaluates the data and summarizes the findings in a comprehensive medical report. All services are performed in-house.The use of NGS technology is of particular interest in the field of tumor diagnostics. Since each tumor may have several genetic driving forces, CeGaT can identify these alterations and help classify which mutations are causative. With the knowledge of these tumor-specific mutations, it is then possible to choose the most optimal therapeutic strategy.CeGaT, founded in 2009 and based in Tübingen, Germany, is accredited according to CAP, CLIA and DIN EN ISO 15189:2014. The company provides human genetics services worldwide.


 
CenterVue SpA
Via San Marco, 9h
35129 Padova - Italy
Tel: +39 049 501 8399
Centervue is an Italian company, a leader in the eye care diagnostic field, that develops systems for the early detection of sight-threatening pathologies, such as diabetic retinopathy, macular degeneration, and glaucoma. Centervue's innovative products are technologically advanced and highly automated. Our goal is to offer user-friendly devices that allow eye practitioners to preserve patients' sight and quality of vision, in particular by detecting preventable diseases.


 
Heidelberg Engineering is a high-tech imaging solutions company which designs, manufactures, and distributes diagnostic instruments for eye care professionals. Its products are used to scan patients' eyes for signs of disease and to assist in the management of patients found to have disease. Early recognition of disease helps to delay and prevent the most common causes of blindness.Typical diseases which can be recognized and tracked with Heidelberg Engineering's technology include glaucoma, AMD, diabetic retinopathy, and macular edema.The company's core technologies include confocal microscopy, scanning lasers and optics, optical coherence tomography, software image analysis and related IT solutions.